Quest Diagnostics lifts FY outlook after broad-based growth powers Q2 beat

Quest Diagnostics

23/07/2026 12:00

    

    Overview
  
US diagnostic testing firm's Q2 revenue rose 10%, beating analyst expectations
Adjusted EPS for Q2 increased 19%, beating analyst expectations
Company raised full-year 2026 revenue and adjusted EPS guidance

    

    Outlook
  
Quest Diagnostics raises 2026 revenue outlook to $11.95 bln-$12.05 bln from $11.78 bln-$11.90 bln
Company lifts 2026 reported diluted EPS forecast to $9.97-$10.17 from $9.58-$9.78
Quest Diagnostics expects 2026 adjusted diluted EPS of $11.05-$11.25, up from $10.63-$10.83

    

    Result Drivers
  
ORGANIC GROWTH - Nearly all revenue growth came from organic gains across physician, hospital, and consumer channels
ADVANCED DIAGNOSTICS - Double-digit revenue growth in Advanced Diagnostics, including Alzheimer's and cardiometabolic tests, contributed to results
CONSUMER CHANNELS - Robust revenue growth from questhealth.com and consumer, wearable, and wellness partners supported results

    
Company press release: ID:nPn70YzCXa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Revenue
Beat
$3.04 bln
$2.97 bln (14 Analysts)
Q2 Adjusted EPS
Beat
$3.12
$2.83 (15 Analysts)
Q2 EPS
 
$2.84
 
Q2 Net Income
 
$320 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Quest Diagnostics Inc is $225.00, about 7.2% above its July 22 closing price of $209.83
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

    

    Reuters Recommended Reads
  
July 23 - France's Eurofins H1 revenue up 2.5% on investment in laboratory network
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook
July 20 - Tempus to acquire Personalis for $1.5 billion

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)